Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy
Tomás Pascual,Aranzazu Fernandez-Martinez,Yash Agrawal,Adam D. Pfefferle,Nuria Chic,Fara Brasó-Maristany,Blanca Gonzàlez-Farré,Laia Paré,Guillermo Villacampa,Cristina Saura,Cristina Hernando,Montserrat Muñoz,Patricia Galván,Xavier Gonzàlez-Farré,Mafalda Oliveira,Miguel Gil-Gil,Eva Ciruelos,Patricia Villagrasa,Joaquín Gavilá,Aleix Prat,Charles M. Perou
DOI: https://doi.org/10.1038/s41523-024-00625-7
2024-03-08
npj Breast Cancer
Abstract:In this study, we performed genomic analyses of cell cycle and tumor microenvironment changes during and after ribociclib and letrozole or chemotherapy in the CORALLEEN trial. 106 women with untreated PAM50-defined Luminal B early breast cancers were randomly assigned to receive neoadjuvant ribociclib and letrozole or standard-of-care chemotherapy. Ki67 immunohistochemistry, tumor-infiltrating lymphocytes quantification, and RNA sequencing were obtained from tissue biopsies pre-treatment, on day 14 of treatment, and tumor specimens from surgical resection. Results showed that at surgery, Ki67 and the PAM50 proliferation scores were lower after ribociclib compared to chemotherapy. However, consistent reactivation of tumor cell proliferation from day 14 to surgery was only observed in the ribociclib arm. In tumors with complete cell cycle arrest (CCCA) at surgery, PAM50 proliferation scores were lower in the ribociclib arm compared to chemotherapy ( p < 0.001), whereas the opposite was observed with tumor cellularity ( p = 0.002). Gene expression signatures (GES) associated with antigen-presenting cells (APCs) and innate immune system activity showed increased expression post-chemotherapy but decreased expression post-ribociclib. Interferon-associated GES had decreased expression with CCCA and increased expression with non-CCCA. Our findings suggest that while both treatment strategies decreased proliferation, the depth and the patterns over time differed by treatment arm. Immunologically, ribociclib was associated with downregulated GES associated with APCs and the innate immune system in Luminal B tumors, contrary to existing preclinical data. Further studies are needed to understand the effect of CDK4/6 inhibition on the tumor cells and microenvironment, an effect which may vary according to tumor subtypes.
oncology